Castle Biosciences Announces Availability of DecisionDx-GBM Biomarker Test for Brain Cancer (Glioblastoma Multiforme) Patients that Predicts Overall Survival to First-Line Standard of Care Treatment

HOUSTON--(BUSINESS WIRE)--DecisionDx-GBM - brain cancer test is a molecular diagnostic test developed at and licensed from The University of Texas M. D. Anderson Cancer Center. The test is used to prospectively predict patient outcome to treatment for glioblastoma multiforme (GBM), the most common form of primary brain cancer.

Back to news